Med-Pharmex manufactures its own products at its facilities in California, with capacity which Dechra plans to use for its own manufacturing strategy over time
Dechra has acquired Med-Pharmex, Inc, a veterinary pharmaceutical manufacturer based in Pomona, California, for £221.5m.
. Ian Page, chief executive Officer at Dechra commented: “I am delighted that we have completed the acquisition of Med-Pharmex, a company that I have been in dialogue with for a number of years. The US market is highly consolidated, therefore this is a unique opportunity to add several new products to our portfolio, enter the US FAP market and improve the manufacturing footprint for our North American business.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A leather-based in vitro model for determining the effect of cosmetics on skin microbesA leather-based in vitro model for determining the effect of cosmetics on skin microbes Cosmetics Skin Microbiome microbiology prebiotics formulation MDPIOpenAccess hsrheinwaal
Read more »
A comprehensive evaluation of microbial differential abundance analysis methods: current status and potential solutions - MicrobiomeBackground Differential abundance analysis (DAA) is one central statistical task in microbiome data analysis. A robust and powerful DAA tool can help identify highly confident microbial candidates for further biological validation. Numerous DAA tools have been proposed in the past decade addressing the special characteristics of microbiome data such as zero inflation and compositional effects. Disturbingly, different DAA tools could sometimes produce quite discordant results, opening to the possibility of cherry-picking the tool in favor of one’s own hypothesis. To recommend the best DAA tool or practice to the field, a comprehensive evaluation, which covers as many biologically relevant scenarios as possible, is critically needed. Results We performed by far the most comprehensive evaluation of existing DAA tools using real data-based simulations. We found that DAA methods explicitly addressing compositional effects such as ANCOM-BC, Aldex2, metagenomeSeq (fitFeatureModel), and DACOMP did have improved performance in false-positive control. But they are still not optimal: type 1 error inflation or low statistical power has been observed in many settings. The recent LDM method generally had the best power, but its false-positive control in the presence of strong compositional effects was not satisfactory. Overall, none of the evaluated methods is simultaneously robust, powerful, and flexible, which makes the selection of the best DAA tool difficult. To meet the analysis needs, we designed an optimized procedure, ZicoSeq, drawing on the strength of the existing DAA methods. We show that ZicoSeq generally controlled for false positives across settings, and the power was among the highest. Application of DAA methods to a large collection of real datasets revealed a similar pattern observed in simulation studies. Conclusions Based on the benchmarking study, we conclude that none of the existing DAA methods evaluated can be applied blindly to any real microbiome dataset.
Read more »
Sony says it believes Xbox owning Call of Duty ‘could influence users’ console choice’ | VGCNew regulatory docs have shown Sony believes Xbox owning Call of Duty 'could influence users’ console choice'.
Read more »